Liposomes versus Lipid Nanoparticles: Comparative Study of Lipid-Based Systems as Oryzalin Carriers for the Treatment of Leishmaniasis

Journal of Biomedical Nanotechnology

Volumn 10, Issue 12, 2014, Pages 3647-3657

  Lopes, R M ^a   Gaspar, M M ^a   Pereira, J ^a   Eleuterio C V ^a   Carvalheiro, M ^a   Almeida, A J ^a   Cruz, M E M ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

Author keywords

Dinitroanilines; In vitro activity; In vivo activity.; Liposomes; Oryzalin; Solid lipid nanoparticles; Visceral leishmaniasis

Indexed keywords

CHEMOTHERAPY; COPYRIGHTS; ENZYME ACTIVITY; NANOPARTICLES;

DINITROANILINES; IN-VITRO; IN-VIVO; ORYZALIN; SOLID LIPID NANOPARTICLE (SLN); VISCERAL LEISHMANIASIS;

LIPOSOMES;

ANTIPROTOZOAL AGENT; LIPID; LIPOSOME; NANOCAPSULE; NITROBENZENE DERIVATIVE; ORYZALIN; SULFANILAMIDE DERIVATIVE;

ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; COMPARATIVE STUDY; CYTOLOGY; DIFFUSION; DRUG EFFECTS; LEISHMANIA; LEISHMANIASIS; MALE; MATERIALS TESTING; MOUSE; PATHOLOGY; PHYSIOLOGY; TREATMENT OUTCOME; ULTRASTRUCTURE;

ANIMALS; ANTIPROTOZOAL AGENTS; DIFFUSION; DINITROBENZENES; LEISHMANIA; LEISHMANIASIS; LIPIDS; LIPOSOMES; MALE; MATERIALS TESTING; MICE; MICE, INBRED BALB C; NANOCAPSULES; SULFANILAMIDES; TREATMENT OUTCOME;

EID: 84928499115     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2014.1874     Document Type: Article

References (56)

1. World Health Organization, (ed.), Expert Committe on the Control of Leishmaniases, Control of the leishmaniases: WHO Techinical Report Series 949, WHO Press, Geneve (2010).
2. E. Handman, Leishmaniasis: Current status of vaccine development. Clin. Microbiol. Rev. 14, 229 (2001).
3. L. Kedzierski, A. Sakthianandeswaren, J. M. Curtis, P. C. Andrews, and P. C. Junk, Leishmaniasis: Current treatment and prospects for new drugs and vaccines. Curr. Med. Chem. 16, 599 (2009).
4. P. Le Pape, Development of new antileishmanial drugs-current knowledge and future prospects. J. Enzym. Inhib. Med. Chem. 23, 708 (2008).
5. B. J. Fennell, J. A. Naughton, J. Barlow, G. Brennan, I. Fairweather, E. Hoey, N. McFerran, A. Trudgett, and A. Bell, Microtubules as antiparasitic drug targets. Expert. Opin. Drug Discov. 3, 501 (2008).
6. Y. M. Traub-Cseko, J. M. Ramalho-Ortigão, A. P. Dantas, S. L. de Castro, H. S. Barbosa, and K. H. Downing, Dinitroaniline herbicides against protozoan parasites: The case of Trypanosoma cruzi. Trends parasitol. 17, 136 (2001).
7. A. Armson, S. W. Kamau, F. Grimm, J. A. Reynoldson, W. M. Best, L. M. MacDonald, and R. C. Thompson, A comparison of the effects of a benzimidazole and the dinitroanilines against Leishmania infantum. Acta Trop. 73, 303 (1999).
8. M. M. Chan, J. Tzeng, T. J. Emge, C. T. Ho, and D. Fong, Structure-function analysis of antimicrotubule dinitroanilines against promastigotes of the parasitic protozoan Leishmania mexicana. Antimicrob. Agents Chemother. 37, 1909 (1993).
9. G. Bhattacharya, M. M. Salem, and K. A. Werbovetz, Antileishmanial dinitroaniline sulfonamides with activity against parasite tubulin. Bioorg. Med. Chem. Lett. 12, 2395 (2002).
10. B. J. Fennell, J. A. Naughton, E. Dempsey, and A. Bell, Cellular and molecular actions of dinitroaniline and phosphorothioamidate herbicides on Plasmodium falciparum: Tubulin as a specific antimalarial target. Mol. Biochem. Parasitol. 145, 226 (2006).
11. M. M. Chan and D. Fong, Inhibition of leishmanias but not host macrophages by the antitubulin herbicide trifluralin. Science 249, 924 (1990).
12. European Food Safety, and Authority, Conclusion on the peer review of the pesticide risk assessment of the active substance oryzalin. EFSA Scientific Report 8, 1 (2010).
13. R. M. Lopes, M. L. Corvo, C. V. Eleutério, M. C. Carvalheiro, E. Scoulica, and M. E. M. Cruz, Formulation of oryzalin (ORZ) liposomes: In vitro studies and in vivo fate. Eur. J. Pharm. Biopharm. 82, 281 (2012).
14. S. Stegemann, F. Leveiller, D. Franchi, H. de Jong, and H. Lindén, When poor solubility becomes an issue: From early stage to proof of concept. Eur. J. Pharm. Sci. 31, 249 (2007).
15. M. E. M. Cruz, S. I. Simes, M. L. Corvo, M. B. F. Martins, and M. M. Gaspar, In Drug Delivery Nanoparticles Formulation and Characterization, edited by Y. Pathak and D. Thassu, Informa Healthcare USA, Inc., New York (2009), Vol. 191, pp. 35-50.
16. M. M. Gaspar, A. Cruz, A. F. Penha, J. Reymão, A. C. Sousa, C. V. Eleutério, S. A. Domingues, A. G. Fraga, A. L. Filho, and M. E. M. Cruz, Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis. Int. J. Antimi-18 Sep 2016 00:28:10 to: crob. Elsevier Agents BV 31, 37 (2008). Publishers
17. C. R. Alving, E. A. Steck, W. L. Chapman, V. B. Waits, L. D. Hendricks, G. M. Swartz, and W. L. Hanson, Therapy of leishmaniasis: Superior efficacies of liposome-encapsulated drugs. Proc. Natl. Acad. Sci. USA 75, 2959 (1978).
18. A. Papagiannaros, C. Bories, C. Demetzos, and P. M. Loiseau, Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations. Biomed. Pharmacother. 59, 545 (2005).
19. J. P. Gangneux, A. Sulahian, Y. J. Garin, R. Farinotti, and F. Derouin, Therapy of visceral leishmaniasis due to Leishmania infantum: Experimental assessment of efficacy of AmBisome. Antimicrob. Agents Chemother. 40, 1214 (1996).
20. A. G. Tempone, R. A. Mortara, H. F. de Andrade, and J. Q. Reimão, Therapeutic evaluation of free and liposome-loaded furazolidone in experimental visceral leishmaniasis. Int. J. Antimicrob. Agents 36, 159 (2010).
21. V. Vanlerberghe, G. Diap, P. J. Guerin, F. Meheus, S. Gerstl, P. Van der Stuyft, and M. Boelaert, Drug policy for visceral leishmaniasis: A cost-effectiveness analysis. Trop. Med. Int. Health 12, 274 (2007).
22. S. L. Croft, S. Sundar, and A. H. Fairlamb, Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 19, 111 (2006).
23. M. Carvalheiro, J. Jorge, C. Eleutério, A. F. Pinhal, A. C. Sousa, J. G. Morais, and M. E. M. Cruz, Trifluralin liposomal formulations active against Leishmania donovani infections. Eur. J. Pharm. Biopharm. 71, 292 (2009).
24. C. Marques, M. Carvalheiro, M. A. Pereira, J. Jorge, M. E. M. Cruz, and G. M. Santos-Gomes, Efficacy of the liposome trifluralin in the treatment of experimental canine leishmaniosis. Vet. J. 178, 133 (2008).
25. R. Lopes, C. V. Eleutério, L. M. D. Gonçalves, M. E. M. Cruz, and A. J. Almeida, Lipid nanoparticles containing oryzalin for the treatment of leishmaniasis. Eur. J. Pharm. Sci. 45, 442 (2012).
26. A. J. Almeida and E. Souto, Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliv. Rev. 59, 478 (2007).
27. E. B. Souto, A. J. Almeida, and R. H. Müller, Lipid Nanoparticles (SLN® , NLC® ) for cutaneous drug delivery: Structure, protection and skin effects. J. Biomed. Nanotechnol. 3, 317 (2007).
28. S. H. Jung, D. H. Lim, S. H. Jung, J. E. Lee, K.-S. Jeong, H. Seong, and B. C. Shin, Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics. Eur. J. Pharm. Sci. 37, 313 (2009).
29. N. P. Aditya, S. Patankar, B. Madhusudhan, R. S. R. Murthy, and E. B. Souto, Arthemeter-loaded lipid nanoparticles produced by modified thin-film hydration: Pharmacokinetics, toxicological and in vivo anti-malarial activity. Eur. J. Pharm. Sci. 40, 448 (2010).
30. A. P. Nayak, W. Tiyaboonchai, S. Patankar, B. Madhusudhan, and E. B. Souto, Curcuminoids-loaded lipid nanoparticles: Novel approach towards malaria treatment. Colloid Surf. B-Biointerfaces 81, 263 (2010).
31. M. L. Corvo, O. C. Boerman, W. J. Oyen, J. C. Jorge, M. E. Cruz, D. J. Crommelin, and G. Storm, Subcutaneous administration of superoxide dismutase entrapped in long circulating liposomes: In vivo fate and therapeutic activity in an inflammation model. Pharm. Res. 17, 600 (2000).
32. G. Rouser, S. Fkeischer, and A. Yamamoto, Two dimensional then layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 5, 494 (1970).
33. J. F. Alzate, A. Alvarez-Barrientos, V. M. González, and A. Jiménez-Ruiz, Heat-induced programmed cell death in Leishmania infantum is reverted by Bcl-X(L) expression. Apoptosis 11, 161 (2006).
34. M. A. Esteves, I. Fragiadaki, R. Lopes, E. Scoulica, and M. E. M. Cruz, Synthesis and biological evaluation of trifluralin analogues as antileishmanial agents. Bioorg. Med. Chem. 18, 274 (2010).
35. D. Plano, Y. Baquedano, D. Moreno-Mateos, M. Font, A. Jiménez-Ruiz, J. A. Palop, and C. Sanmartín, Selenocyanates and diselenides: A new class of potent antileishmanial agents. Eur. J. Med. Chem. 46, 3315 (2011).
36. H. Castro, F. Teixeira, S. Romao, M. Santos, T Cruz, M. Flórido, R. Appelberg, P. Oliveira, F. Ferreira-da-Silva, and A. M. Tomás, Leishmania mitochondrial peroxiredoxin plays a crucial peroxidaseunrelated role during infection: Insight into its novel chaperone activity. PLoS Pathog. 7, e1002325 (2011).
37. P. A. Buffet, A. Sulahian, Y. J. Garin, N. Nassar, and F. Derouin, Culture microtitration: A sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrob. Agents Chemother. 39, 2167 (1995).
38. P. Escobar, V. Yardley, and S. L. Croft, Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice. Antimicrob. Agents Chemother. 45, 1872 (2001).
39. S. Nema, R. J. Brendel, and R. Washkuhn, Encyclopedia of Pharmaceutical Technology, 3rd edn., edited by James Swarbrick, Informa Healthcare USA, Inc., New York (2007), Vol. 1, pp. 1622-1645.
40. T. M. Allen, G. A. Austin, A. Chonn, L. Lin, and K. C. Lee, Uptake of liposomes by cultured mouse bone marrow macrophages: Influence of liposome composition and size. Biochim. Biophys. Acta 1061, 56 (1991).
41. T. M. Riddick, Control of Colloid Stability Through Zeta Potential: With a Closing Chapter on Its Relationship to Cardiovascular Disease, Zeta-Meter Inc., Livingston Pub. Co., Wynnewood (1968).
42. M. V. Zhukova, O. V, Romanenko, V. A. Nikolaevich, and M. A. Kisel, Hemolytic properties of miltefosine in liposomes of various lipid compositions. Pharm. Chem. J. 44, 507 (2010).
43. G. W. Boswell, D. Buell, and I. Bekersky, AmBisome (liposomal amphotericin B): A comparative review. J. Clin. Pharmacol. 38, 583 (1998).
44. M. D. Joshi and R. H. Müller, Lipid nanoparticles for parenteral delivery of actives. Eur. J. Pharm. Biopharm. 71, 161 (2009).
45. S. Gupta, A, Pal, and S. P. Vyas, Drug delivery strategies for therapy of visceral leishmaniasis. Expert Opin. Drug Deliv. 7, 371 (2010).
46. L. H. Reddy, R. K. Sharma, K. Chuttani, A. K. Mishra, and R. S. R. Murthy, Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice. J. Control Release 105, 185 (2005).
47. T. M. Allen, C. B. Hansen, and L. S. Guo, Subcutaneous administration of liposomes: A comparison with the intravenous and intraperitoneal routes of injection. Biochim. Biophys. Acta 1150, 9 (1993).
48. S. Chono, Y. Taushi, and K. Morimoto, Influence of particle size on the distribuitions of liposomes to artherosclerotic lesions in mice. Drug Dev. Ind. Pharm. 32, 125 (2006).
49. T. M. Houng, H. Harashima, and H. Kiwada, In vivo studies on the role of complement in the clearance of liposomes in rats and guinea pigs. Biol. Pharm. Bull. 22, 515 (1999).
50. H. Harashima, T. M. Houng, T. Ishida, Y. Manabe, H. Matsuo, and H. Kiwada, Synergistic effect between size and cholesterol content in enhanced hepatic uptake clearance of liposomes through complement activation in rats. Pharmaceu. Res. 13, 1704 (1996).
51. T. M. Allen and C. Hansen, Pharmacokinetics of stealth versus conventional liposomes: Effect of dose. Biochim. Biophys. Acta 1068, 133 (1991).
52. R. M. Abra and C. A. Hunt, Liposome disposition in vivo. III. Dose and vesicle-size effects. Biochim. Biophys. Acta 666, 493 (1981).
53. S. M. Moghimi, A. C. Hunter, and J. C. Murray, Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol. Rev. 53, 283 (2001).
54. S. M. Moghimi, C. J. Porter, I. S. Muir, L. Illum, and S. S. Davis, Non-phagocytic uptake of intravenously injected microspheres in rat spleen: Influence of particle size and hydrophilic coating. Biochem. Biophys. Res. Commun. 177, 861 (1991).
55. S. Medda, P. Jaisankar, R. K. Manna, B. Pal, V. S. Giri, and M. K. Basu, Phospholipid microspheres: A novel delivery mode for targeting antileishmanial agent in experimental leishmaniasis. J. Drug Target 11, 123 (2003).
56. S. Medda, S. Mukhopadhyay, and M. K. Basu, Evaluation of the invivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal forms. J. Antimicrob. Chemother. 44, 791 (1999).